Figure 1. Micrographs of spinal cord motoneurons showing SOD1-immunoreactive inclusions.
Image credit: Forsberg, et. al. 2010 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Paulo Gontijo Award for ALS Research
Sponsor: The Gontijo family
Description: The PG award recognizes the research of early career scientists (up to 40 years) in the ALS field. The winner of the award will present the work to the scientific community and will receive the prize of $20,000 USD and a gold medal, delivered at the opening of the 28th International Symposium on ALS / MND, to be held in Boston, USA, December 2017. All expenses, including cash value, are fully provided by the Gontijo family. The funds from donations to the IPG are fully reverted to the maintenance of other projects of the Institute.
Deadline: Application due by July 1, 2017.



NEW! Harrington Rare Disease Scholar Award
Sponsor: Takeda Pharmaceuticals
Description: he Harrington Rare Disease Scholar Award supports breakthrough research for therapeutic discoveries in rare diseases that aims to advance them into therapies. The program is overseen by Harrington Discovery Institute, a nonprofit initiative that helps academic researchers translate their most promising inventions into new medicines. The award, which is sponsored by Takeda Pharmaceuticals, provides access to Takeda’s research and development experts and resources. Current target areas of interest include all rare diseases, but of particular interest are rare diseases in the areas of neurology and gastroenterology. The award is at least $150,000 USD and is up to $1 million USD.
Deadline: Letter of Intent due by July 19, 2017.



NEW! MND Research Grants
Sponsor: MND Australia
Description: Seed-funding for research that is innovative and has a clear relationship to the causes, treatments and cures of MND or the support of people living with MND. Applicants must have Australian permanent residency or be Australian citizens. Funding is up to $100,000 AUD for one year.
Deadline: Application due by August 25, 2017.



NEW! Postdoctoral Research Fellowships
Sponsor: MND Australia
Description: Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must have Australian permanent residency or be Australian citizens. Salary for a full-time research fellow will be funded at $100,000 p.a. for a period of up to three years.
Deadline: Application due by August 25, 2017.



NEW! The Betty Laidlaw MND Research Prize
Sponsor: MND Australia
Description: The Betty Laidlaw MND Research Prize aims to reward an outstanding mid-career researcher in Australia with a demonstrated background of excellence in neuroscience research. The Prize is for an innovative 12-month project to advance the understanding of classical MND with a clear potential for effective treatments. It aims to support research commencing in the calendar year 2018. Funding is up to $250,000 AUD for one year.
Deadline: Application due by August 25, 2017.



AFM-Telethon Research Grants
Sponsor: AFM-Telethon
Description: Funding priorities include:(1) basic research that increases our understanding of the neuromuscular system or (2) development of therapeutics for rare neuromuscular diseases. The maximum award for research grants is 200,000€ for multi-research teams and multi-year projects. However, the average amount per project is 40,000 €/year. Research groups located outside France are encouraged to collaborate with labs in France.
Deadline: Application due by July 4, 2017.



AFM-Telethon Trampoline Grants
Sponsor: AFM-Telethon
Description: Trampoline grants are intended to support investigators early in their professional career and/or early stage innovative projects. This grant is awarded for a maximum of 50,000 euros for one year. Funding priorities include:(1) basic research that increases our understanding of the neuromuscular system or (2) development of therapeutics for rare neuromuscular diseases. Research groups located outside France are encouraged to collaborate with labs in France.
Deadline: Application due by July 4, 2017.



Rapid Response 2017 (FTD)
Sponsor: Weston Brain Institute
Description: This grant program provides seed funding for high-risk, high-reward, translational research projects on neurodegenerative diseases of aging including FTD. The maximum award is $200,000 per project over up to 18 months. Eligible principal applicants must be researchers working in Canada at least 30% of the time at or above the level of Postdoctoral Fellow, and affiliated with a Canada Revenue Agency-qualified donee institution located in Canada.
Deadline: Letter of Intent due by July 5, 2017.



Accelerating Drug Discovery for FTD
Sponsor: The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration
Description: This grant program seeks to accelerate and support innovative drug discovery programs for FTD. Funding priorities include (1)development and testing of novel high throughput screening assays; (2) identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies; (3) testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept; (4) development and/or characterization of new model organisms or cellular models to support drug discovery efforts. Award is $100,000-$150,000 for 1 year with the potential for renewal.
Deadline: Letter of Intent due by July 31, 2017.



Judith and Jean Pape Adams ALS Research Grants
Sponsor: The Judith and Jean Pape Adams Foundation
Description: These grants support research that is aimed at discovering the causes of and finding a cure for ALS. The Foundation funds research that is innovative and aggressive. The research must be of high scientific merit. We encourage partnerships and collaborative efforts in proposing initiatives to fill gaps not currently being investigated and that involve novel approaches. The foundation will begin receiving applications in March 2017.
Deadline: Application due by August 4, 2017.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by September 30, 2017.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association. Applications received beginning September 8, 2017.
Deadline: Application due by November 3, 2017.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Healthcare Research Grants
Sponsor: Motor Neurone Disease Association (MNDA)
Description: MNDA invests in research that fills knowledge gaps in clinical management of MND, adding to the evidence base and driving improvements in quality of care for people affected by MND.  
Deadline: Now accepting applications.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail